Zacks Analyst Blog Puts Johnson & Johnson in a 2027 “beyond AI” demand theme

A fresh note from Zacks, circulated by Yahoo Finance, placed Johnson & Johnson (JNJ) within a broader investment theme focused on demand that extends past the current wave of artificial intelligence spending. The blog, titled around Zacks’ analyst takeaways, grouped Johnson & Johnson with Abbott Laboratories and Stryker in healthcare, and with Waste Management and Republic Services in waste services, framing each as a participant in “long-term demand opportunities beyond AI” looking ahead to 2027.

In the post distributed through Yahoo Finance, Zacks did not present a detailed company-by-company earnings forecast or new regulatory filing information. Instead, it used the five-company shortlist to underscore a sector argument: certain categories have baseline consumption characteristics that continue even when macro attention shifts to technology themes.

For Johnson & Johnson, the mention indicates that Zacks’ analysts view the company’s healthcare exposure as part of a durable demand set, rather than a direct proxy for AI-driven capex or enterprise tech cycles. Johnson & Johnson’s business spans pharmaceuticals and medical devices, areas where demand is often influenced by demographics, chronic care patterns, and replacement cycles for healthcare equipment and supplies. The Zacks framing, as relayed by Yahoo Finance, emphasized durability rather than timing.

The inclusion of Abbott Laboratories and Stryker alongside Johnson & Johnson points to a similar thesis within healthcare: not all medical demand is discretionary or purely cyclical. Abbott’s mix includes diagnostics and established nutrition-related categories, while Stryker is known for orthopedic and surgical technologies. Zacks’ blog positioned the combined healthcare set under a common “long-term demand” narrative, while avoiding any claim in the Yahoo-distributed excerpt about near-term margin expansion or sales acceleration.

Outside healthcare, the same Zacks note connected its “beyond AI” theme to waste management firms Waste Management and Republic Services. That linkage implies that Zacks is treating waste services as an analogous category with persistent operational needs, where volume and collection contracts are supported by underlying municipal and industrial activity. Again, the Yahoo Finance-disseminated item did not provide fresh contract details or operational metrics in the materials available for this review.

Zacks’ argument, in other words, is less about immediate catalysts and more about positioning. The blog’s headline framing suggests that the relevant watch for 2027 is demand persistence in essential services, including healthcare delivery and waste collection. But the Yahoo Finance-hosted item did not disclose the specific quantitative assumptions behind the 2027 time horizon, nor did it enumerate segment-level growth drivers for Johnson & Johnson such as particular drug launches, device adoption rates, or reimbursement impacts.

For readers tracking Johnson & Johnson, the practical takeaway is that at least one sell-side framework is looking past technology hype and emphasizing longer-cycle fundamentals. Still, the post did not provide the kind of detail that would allow outsiders to verify the assumptions, such as updated segment revenue ranges, guidance revisions, or identified product milestones for Johnson & Johnson.

What to watch next is whether Johnson & Johnson’s subsequent disclosures, including quarterly results and any updated outlook language, reflect the kind of durability that Zacks is pointing to. If Zacks updates its model work, analysts typically follow with more specific drivers, such as growth rates by franchise, commodity or input cost trends, and any changes in competitive or regulatory conditions. Until then, this item is best read as a thematic positioning rather than a definitive forecast.